Floatz logo

154 assets in Colon Carcinoma

Therapeutic assets addressing Colon Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Colon Carcinoma
AkesoP4BB (70)
Oxaliplatin
Colon Carcinoma
Sun Yat-sen UniversityP3BB (70)
Pertuzumab
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3BB (69)
Encorafenib
Colon Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCSP3BB (68)
Irinotecan
Colon Carcinoma
SCRI Development Innovations, LLCP3BB (68)
Palbociclib
Colon Carcinoma
Lebanese UniversityP2BB (68)
Trastuzumab
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3BB (68)
Binimetinib
Colon Carcinoma
AIO-Studien-gGmbHP3BB (66)
Macrogols
Colon Carcinoma
University Medical Center Ho Chi Minh City (UMC)P4BB (66)
Atezolizumab
Colon Carcinoma
Baylor College of MedicineP3BB (64)
Tipiracil
Colon Carcinoma
Academic and Community Cancer Research UnitedP2BB (64)
Trifluridine
Colon Carcinoma
Academic and Community Cancer Research UnitedP2BB (64)
Dasatinib
Colon Carcinoma
Anne NoonanP2B (63)
Panitumumab
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3B (63)
Cetuximab
Colon Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCSP3B (62)
Cyclophosphamide
Colon Carcinoma
Essen BiotechP2B (61)
Dexasone
Colon Carcinoma
Institute of Oncology LjubljanaP4B (61)
Lidocaine
Colon Carcinoma
Institute of Oncology LjubljanaP4B (61)
Nepenthe
Colon Carcinoma
Tel Aviv UniversityP4B (61)
Balstilimab
Colon Carcinoma
City of Hope Medical CenterP2B (60)
Botensilimab
Colon Carcinoma
City of Hope Medical CenterP2B (60)
Capecitabine
Colon Carcinoma
Sun Yat-sen UniversityP3B (60)
Nivolumab
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3B (60)
Muamycin
Colon Carcinoma
City of Hope Medical CenterP4B (58)
Pembrolizumab
Colon Carcinoma
Ismail GögenurP2B (58)
Celecoxib
Colon Carcinoma
University of CopenhagenP3B (57)
Docetaxel
Colon Carcinoma
Sun Yat-sen UniversityP3B (57)
Aspirin
Colon Carcinoma
M.D. Anderson Cancer CenterP3B (56)
Icosapent Ethyl
Colon Carcinoma
Massachusetts General HospitalP3B (56)
Ipilimumab
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3B (56)
Tislelizumab
Colon Carcinoma
fan liP3B (56)
Everolimus
Colon Carcinoma
Fudan UniversityP2CCC (55)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Colon Carcinoma
John Strickler, M.D.P2CCC (55)
Gastrografin
Colon Carcinoma
Region SkaneP3CCC (54)
Prucalopride
Colon Carcinoma
Region SkaneP3CCC (54)
Sodium Phosphate
Colon Carcinoma
Region SkaneP3CCC (54)
Sodium Picosulfate
Colon Carcinoma
Region SkaneP3CCC (54)
Apsolol
Colon Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Artesunate
Colon Carcinoma
Metanoic Health Ltd.P2CCC (53)
Bms 986253
Colon Carcinoma
The Netherlands Cancer InstituteP2CCC (53)
Capivasertib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Crizotinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipatasertib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Levofolinic Acid
Colon Carcinoma
Gruppo Oncologico del Nord-OvestP2CCC (53)
Nbt-Nm108
Colon Carcinoma
Howard S. Hochster, MDP2CCC (53)
Showing 1 to 50 of 154 assets
PreviousPage 1 of 4Next